Cetera Investment Advisers Boosts Holdings in Bio-Rad Laboratories, Inc. $BIO

Cetera Investment Advisers increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 12.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,932 shares of the medical research company’s stock after buying an additional 215 shares during the quarter. Cetera Investment Advisers’ holdings in Bio-Rad Laboratories were worth $471,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BIO. GeoWealth Management LLC lifted its holdings in Bio-Rad Laboratories by 342.9% during the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. Curat Global LLC purchased a new position in Bio-Rad Laboratories during the first quarter valued at approximately $34,000. Allworth Financial LP lifted its holdings in Bio-Rad Laboratories by 260.0% during the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 104 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Bio-Rad Laboratories during the fourth quarter valued at approximately $131,000. Finally, Skylands Capital LLC purchased a new position in Bio-Rad Laboratories during the first quarter valued at approximately $122,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.5%

NYSE:BIO opened at $285.71 on Monday. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The firm has a market cap of $7.73 billion, a P/E ratio of 24.36 and a beta of 0.90. The firm has a 50-day simple moving average of $251.27 and a 200-day simple moving average of $254.15.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating the consensus estimate of $1.93 by $0.68. The business had revenue of $651.60 million during the quarter, compared to analyst estimates of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.11 earnings per share. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BIO has been the topic of several analyst reports. Wall Street Zen raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Citigroup cut their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. UBS Group cut their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company boosted their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average target price of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.